Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Orelabrutinib · ICP-022

Small molecule · Inhibitor of Bruton's tyrosine kinase (BTK) · developed by Beijing InnoCare Pharma Tech Co.

Phase 3 Most advanced trial
1 Registered trials

What is Orelabrutinib?

Orelabrutinib is a small molecule that binds and inhibits Bruton's tyrosine kinase (BTK), blocking B-cell antigen receptor signaling and BTK-mediated survival pathways in B cells. It is being studied in primary progressive multiple sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ICP-022
Drug type
Small molecule
Targets
Bruton's tyrosine kinase (BTK)
Mechanism
Inhibitor of Bruton's tyrosine kinase (BTK)
Pathways
B-cell antigen receptor (BCR) signaling, BTK-mediated B-cell survival signaling
Therapy area
Neurology
Developer
Beijing InnoCare Pharma Tech Co., Ltd.
In trials of
ZBIO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
WJA5UO9E10

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07067463 Phase 3 Multiple Sclerosis (MS) Primary Progressive Recruiting ZBIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Sclerosis (MS) Primary Progressive

Other drugs acting on BTK

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.